China Resources Pharmaceutical Group (STU:640) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:640 China Resources Pharmaceutical Group Ltd STU:640
60 GF Score
Price €0.51
GF Value €0.64
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is China Resources Pharmaceutical Group FFO per Share?

FFO per Share only applies to REITs.

STU:640
60GF Score
China Resources Pharmaceutical Group Ltd STU:640
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is China Resources Pharmaceutical Group (STU:640) Overvalued in 2026?

Based on GuruFocus' analysis, China Resources Pharmaceutical Group stock appears to be undervalued. The current stock price of €0.51 is trading 20.3% below its estimated GF Value™ of €0.64. GuruFocus considers China Resources Pharmaceutical Group to be Modestly Undervalued.

Key valuation signals for STU:640:

  • FFO per Share:
  • GF Value™: €0.64 vs. price of €0.51 (20.3% below fair value)
  • GF Score™: 60/100 with 3 warning signs

No single metric tells the full story. See the STU:640 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


China Resources Pharmaceutical Group Business Description

Other Exchanges 03320:Hong Kong
Address 26 Harbour Road, Room 4104-05, 41st Floor, China Resources Building, Wanchai, HKG
China Resources Pharmaceutical Group Ltd is principally engaged in the manufacture, distribution and retail of pharmaceutical and healthcare products. Specifically, the Group has four reportable segments as follows: Pharmaceutical manufacturing business, Pharmaceutical distribution business, Pharmaceutical retail business , and Other business operations. The company generates majority of its revenue from the Pharmaceutical distribution business.
60GF Score

Get the complete analysis for STU:640

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.51
Price
€0.64
GF Value